Related Experiment Video
Updated: Jul 18, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Drug-eluting stent era: will we improve 5-year outcomes?
1Interventional Cardiology Section, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Harvard Medical School, Boston, Massachusetts, USA. dcutlip@bidmc.harvard.edu
Coronary Artery Disease
|November 23, 2006
Summary
Drug-eluting stents show promise for improving 5-year outcomes after coronary stenting, particularly in diabetic patients. Further research is needed to assess their role in preventing later disease progression and reducing repeat procedures.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
Context:
- Five-year outcomes post-coronary stenting are influenced by in-stent restenosis and non-stented segment disease progression.
- Atherosclerosis progression and vulnerable plaque instability contribute to long-term adverse events.
Purpose:
- To evaluate the impact of drug-eluting stents (DES) on five-year outcomes following coronary stenting.
- To explore the potential of DES in reducing restenosis, repeat revascularization, myocardial infarction, and death.
Summary:
- Drug-eluting stents demonstrate significant anti-restenosis benefits across various lesion types and patient groups, including complex cases and diabetics.
- These benefits are expected to translate into improved five-year outcomes, with a reduced need for revascularization.
- DES may particularly benefit diabetic patients, who face higher risks of restenosis and mortality after bare-metal stent implantation.
Impact:
- DES offer a hopeful outlook for improved long-term cardiovascular outcomes.
- Future studies will investigate DES's role in managing late disease progression and compare them with coronary artery bypass surgery.
- Optimal outcomes likely involve judicious DES use combined with aggressive secondary prevention strategies.
